Neisseria meningitidis. Lipopolysakkariders patofysiologiske rolle ved meningokoksygdom og septisk shock

Mie Østergaard Pedersen; Dan Sonne Pedersen; Michael Pedersen; Milena Penkowa

Neisseria meningitidis. Lipopolysakkariders patofysiologiske rolle ved meningokoksygdom og septisk shock

Mie Østergaard Pedersen, Dan Sonne Pedersen, Michael Pedersen, Milena Penkowa

1 Citationer (Scopus)

Abstract

A major pro-inflammatory and toxic component of N. meningitidis is lipopolysaccharide (LPS). LPS contributes to severe symptoms of meningococcal disease, septic shock and severe coagulopathy, in part by increasing pro-inflammatory mechanisms and reactive oxygen species. Recent technologies have increased the likelihood of developing an anti-meningococcal immunization strategy based upon the virulence of LPS which may lead to a vaccination against this important pathogen including serogroup B disease. This review summarizes recent findings that may provide a safe, effective prophylaxis and therapy.
Udgivelsesdato: 2008-Feb-4

Bidragets oversatte titel	Neisseria meningitidis. The pathophysiological role of lipopolysaccharides in association with meningococcal disease and septic shock
Originalsprog	Dansk
Tidsskrift	Ugeskrift for læger
Vol/bind	170
Udgave nummer	6
Sider (fra-til)	421-6
Antal sider	5
ISSN	0041-5782
Status	Udgivet - 2008

Citationsformater

@article{98d89040f91211ddb219000ea68e967b,

title = "Neisseria meningitidis. Lipopolysakkariders patofysiologiske rolle ved meningokoksygdom og septisk shock",

abstract = "A major pro-inflammatory and toxic component of N. meningitidis is lipopolysaccharide (LPS). LPS contributes to severe symptoms of meningococcal disease, septic shock and severe coagulopathy, in part by increasing pro-inflammatory mechanisms and reactive oxygen species. Recent technologies have increased the likelihood of developing an anti-meningococcal immunization strategy based upon the virulence of LPS which may lead to a vaccination against this important pathogen including serogroup B disease. This review summarizes recent findings that may provide a safe, effective prophylaxis and therapy. Udgivelsesdato: 2008-Feb-4",

author = "Pedersen, {Mie {\O}stergaard} and Pedersen, {Dan Sonne} and Michael Pedersen and Milena Penkowa",

note = "Keywords: Anti-Bacterial Agents; Humans; Lipopolysaccharides; Meningococcal Infections; Meningococcal Vaccines; Neisseria meningitidis; Neisseria meningitidis, Serogroup B; Shock, Septic; Virulence",

year = "2008",

language = "Dansk",

volume = "170",

pages = "421--6",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "6",

}

TY - JOUR

T1 - Neisseria meningitidis. Lipopolysakkariders patofysiologiske rolle ved meningokoksygdom og septisk shock

AU - Pedersen, Mie Østergaard

AU - Pedersen, Dan Sonne

AU - Pedersen, Michael

AU - Penkowa, Milena

N1 - Keywords: Anti-Bacterial Agents; Humans; Lipopolysaccharides; Meningococcal Infections; Meningococcal Vaccines; Neisseria meningitidis; Neisseria meningitidis, Serogroup B; Shock, Septic; Virulence

PY - 2008

Y1 - 2008

N2 - A major pro-inflammatory and toxic component of N. meningitidis is lipopolysaccharide (LPS). LPS contributes to severe symptoms of meningococcal disease, septic shock and severe coagulopathy, in part by increasing pro-inflammatory mechanisms and reactive oxygen species. Recent technologies have increased the likelihood of developing an anti-meningococcal immunization strategy based upon the virulence of LPS which may lead to a vaccination against this important pathogen including serogroup B disease. This review summarizes recent findings that may provide a safe, effective prophylaxis and therapy. Udgivelsesdato: 2008-Feb-4

AB - A major pro-inflammatory and toxic component of N. meningitidis is lipopolysaccharide (LPS). LPS contributes to severe symptoms of meningococcal disease, septic shock and severe coagulopathy, in part by increasing pro-inflammatory mechanisms and reactive oxygen species. Recent technologies have increased the likelihood of developing an anti-meningococcal immunization strategy based upon the virulence of LPS which may lead to a vaccination against this important pathogen including serogroup B disease. This review summarizes recent findings that may provide a safe, effective prophylaxis and therapy. Udgivelsesdato: 2008-Feb-4

M3 - Tidsskriftartikel

C2 - 18252172

SN - 0041-5782

VL - 170

SP - 421

EP - 426

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 6

ER -